Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact - Investopedia

Summary

The article discusses the impact of Pfizer's withdrawal from a biopharma collaboration with Sangamo Therapeutics on developing a gene therapy for hemophilia, which significantly affected Sangamo's stock value. The key concept 'biopharma' ties into the biotechnology and gene therapy focus of their joint project, giroctocogene fitelparvovec. Tags identify relevant topics and stakeholders, including Sangamo, Pfizer, and the drug's development.